YesPress Profile / Medtech Operator
Thomas Arnold
He runs a company whose flagship product fits under a shirt and disappears into a day. The ambition does neither.
Tom Arnold, in the chair at ViCentra
He runs a company whose flagship product fits under a shirt and disappears into a day. The ambition does neither.
In May 2026, on a stage at the 60th DDG Diabetes Congress in Berlin, ViCentra pulled the cover off a system that does something quietly radical: it controls insulin therapy from a phone people already carry, not a separate handset they have to remember. Tom Arnold has been CEO for fifteen months. This was his unveiling.
The hardware is Kaleido, a reusable patch pump that ViCentra calls the smallest, lightest and most precise in its class. The brains are Diabeloop's self-learning DBLG2 algorithm. The eyes are a Dexcom G7 continuous glucose monitor. Stitched together, they form a hybrid closed loop - a system that reads, decides and doses with far less human intervention than the alternatives. First commercial deliveries were planned for Germany and the Netherlands in the summer of 2026.
That is the unusual part of Arnold's job. Most insulin pumps look like medical equipment because they are. Kaleido comes in different colors and tubing lengths, the kind of choices you make about a watch, not a device prescribed to you. The bet underneath the whole company is that wanting to wear something and having to wear it are not the same feeling, and the second can be engineered closer to the first.
"We are making automated insulin delivery simpler, more flexible and easier to live with."
Tom Arnold, on the Kaleido launch
Read Arnold's résumé and the ViCentra job looks like a strange place to land. Medtronic. Boston Scientific. Sorin Group. PROCEPT BioRobotics. These are the names that own the trade-show floor, the companies a medtech career is supposed to climb toward, not away from. He spent more than seven years at Medtronic alone, finishing as VP of commercial strategy and enablement.
Then in February 2025 he took the top seat at a Utrecht startup with roughly 2,500 active users across Europe. The math is almost provocative. You can carry 2,500 customers in a spreadsheet. The thing Arnold appears to have wanted was not scale on day one but the chance to decide what scale would look like.
His career has a throughline that explains the leap. At Medtronic, he helped launch the world's first hybrid closed-loop insulin pump system - the category that ViCentra now competes in. He has done the hard part once already: convincing payers, clinicians and patients that a closed loop is worth the switch. At ViCentra he gets to do it again, on his terms, with hardware small enough to be a selling point rather than an apology.
Arnold describes himself in a specific phrase: "both a MedTech leader and a father." It is the rare CEO line that tells you something. The work is not abstract to him. He understands what it means for a device to be intuitive enough to fade into the background, and what it costs a household when it isn't.
That perspective shapes the product language at ViCentra more than any spec sheet does. The pitch is rarely about milligrams or microliters first. It is about freedom, discretion and the ability to live on your own terms. Arnold talks about insulin therapy as something that should accommodate a life rather than dictate one - the difference between a tool you tolerate and one you reach for.
"As both a MedTech leader and a father, I understand the impact that well-designed, intuitive technology can have. Kaleido's approach resonates deeply."
Tom Arnold, on joining ViCentra
Kaleido: a reusable patch pump pitched as the smallest, lightest and most precise in its class, sold with color and tubing options most medical devices never bother to offer.
Diabeloop's DBLG2 self-learning algorithm paired with the Dexcom G7 CGM, forming a hybrid closed loop that reads glucose and adjusts dosing automatically.
Therapy controlled from a smartphone people already own, not a dedicated handset - one less object to charge, carry and not forget.
Scale across Europe starting with Germany and the Netherlands, ready the next generation, and prepare the system for entry into the US market.
It is easy to read "smallest and lightest" as marketing filler. For Arnold it is closer to the entire thesis. A device people barely notice is a device they wear correctly, consistently, without resentment. Compliance, in medical terms, is mostly a design problem wearing a clinical disguise. Shrink the friction and you change the outcome.
That is why the smartphone control matters more than it sounds. Removing the separate handset is not a feature so much as a subtraction - one fewer thing standing between a person and their own routine. ViCentra is betting that the company which removes the most friction, not the one that adds the most features, wins the next decade of diabetes care.
Arnold's task is to turn that conviction into a real business across borders, regulators and reimbursement systems that rarely agree on anything. The financing is in place. The product is shipping. The category is one he helped invent. What is left is the part no spec sheet measures: convincing a continent, and then a country across an ocean, that the smallest option is also the best one.
French maker of the DBLG2 self-learning algorithm at the core of the Kaleido closed loop.
The G7 continuous glucose monitor supplies the real-time data the system doses against.
Where Arnold helped launch the first hybrid closed-loop system - the playbook he now runs at a startup's pace.